SPY765.80+0.02%QQQ737.05+0.07%BTC/USD82,999.90−0.55%DIA514.14+0.02%GLD378.31+0.11%TLT78.69+0.09%
Benzinga

TuHURA Biosciences Inc (HURA) Stock Price, Quote, News & History

HURANASDAQ
Trade with Public
Trade with Public
$2.09
-0.01-0.48%
At close: Sep 28, 5:00 PM EST
$2.06
-0.03-1.44%
After Hours: 4:05 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

TuHURA Biosciences (HURA) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$2.06
Close
$2.09
Volume / Avg.
375.39K / 340.09K
Day Range
$2.03 - $2.16
52 Wk Range
0.41 - 3.43
Market Cap
$131.28M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
46
Short Interest
12.74%
Days to Cover
32.58

Recent TuHURA Biosciences Inc News

PRO
FDA Gives Clearance To TuHURA Biosciences IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related Cancers

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target

Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
Benzinga Newsdesk

PRO
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share
Benzinga Newsdesk

PRO
TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an
Benzinga Newsdesk

PRO
TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share
Benzinga Newsdesk

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-29.69M
Investing Cash Flow (TTM)
-213.67K
Financing Cash Flow (TTM)
22.39M
Free Cash Flow (TTM)
-29.90M
Capital Expenditure (TTM)
-213.67K
Net Change in Cash (TTM)
-7.52M

Analyst Trends and Forecast

0
0
0
0
Apr
0
0
0
0
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$142.29M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
7.34
Earnings Yield % (TTM)
-25.71%
Earnings Yield % (FWD)
-29.05%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.29

Company Debt

Total Debt
$8.77M
LT Debt
$3.60M
LT Debt Issuance (TTM)
$6.60M
LT Debt Repayment (TTM)
-$2.80M
Total Cash
$995.98K
Debt to Equity
0.50
Issuance of Debt (TTM)
$3.80M
Repayment of Debt (TTM)
-$2.80M

Key Statistics

Open
$2.06
Close
$2.09
Volume / Avg.
375.39K / 340.09K
Day Range
$2.03 - $2.16
52 Wk Range
0.41 - 3.43
Market Cap
$131.28M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
46
Short Interest
12.74%
Days to Cover
32.58

About

Sector
Health Care
Industry
Biotechnology
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy TuHURA Biosciences (HURA) stock?

A

You can purchase shares of TuHURA Biosciences (NASDAQ:HURA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TuHURA Biosciences (HURA) competitors?

Q

What is the forecast, or price target, for TuHURA Biosciences (HURA) stock?

A

TuHURA Biosciences has a consensus price target of $9.50.

Q

What is the current price for TuHURA Biosciences (HURA)?

A

The stock price for TuHURA Biosciences (NASDAQ: HURA) is $2.06 last updated September 28, 2026 at 4:05 PM EDT.

Q

Does TuHURA Biosciences (HURA) pay a dividend?

A

There are no upcoming dividends for TuHURA Biosciences.

Q

When is TuHURA Biosciences (NASDAQ:HURA) reporting earnings?

A

TuHURA Biosciences does not have any upcoming earnings scheduled.

Q

Is TuHURA Biosciences (HURA) going to split?

A

There is no upcoming split for TuHURA Biosciences.

Q

What sector and industry does TuHURA Biosciences (HURA) operate in?

A

TuHURA Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved